Synthesis, anticancer and FGFR1 inhibitory activity of isoindolo isoindolo[2,1-a][1,2,4]triazino[2,3-c]quinazoline derivatives

dc.contributor.authorVoskoboynik, O. Yu.
dc.contributor.authorStarosyla, S. A.
dc.contributor.authorProtopopov, M. V.
dc.contributor.authorVolynets, H. P.
dc.contributor.authorShyshkina, S. V.
dc.contributor.authorYarmoliuk, S. M.
dc.contributor.authorKovalenko, S. I.
dc.contributor.authorВоскобойнік, Олексій Юрійович
dc.contributor.authorСтаросила, С. А.
dc.contributor.authorПротопопов, М. В.
dc.contributor.authorВолинець, Г. П.
dc.contributor.authorШишкіна, С. В.
dc.contributor.authorЯрмолюк, С. М.
dc.contributor.authorКоваленко, Сергій Іванович
dc.date.accessioned2016-10-31T20:48:12Z
dc.date.available2016-10-31T20:48:12Z
dc.date.issued2016
dc.description.abstractpresented manuscript describes the synthesis, antitumor and fgfr1 inhibitory activity of novel isoindolo[2,1-a] [1,2,4]triazino[2,3-c]quinazolines. it was shown that mentioned above substances may be prepared by interaction of 3-(2-amino-3-r2-5-r3-phenyl)-6-r1-1,2,4-triazin-5(2h)-ones with 2-formylbenzoic and 6-formyl-,3-dimethoxybenzoic (opianic) acids in acetic acid. it was shown that proper 2-(2-oxo-3-r-6,7-dihydro-2h-[1,2,4]triazino[2,3-c]quinazolin- 6-yl)benzoic acids (or corresponded dimethoxysubstituted analogues) may be considered as intermediates of the reaction. Spectral properties of synthesized compounds were studied, it was shown that protons in position 8 were observed at low feld as result of the presence of hydrogen bond between hydrogen at position 8 and oxygen at position 10. the anticancer assay data allowed to identify synthesized compounds as promising antitumor agents. the fgfr 1 inhibitory activity of synthesized compounds was detected and docking study aimed to the evaluation of mentioned action was conducted.uk_UK
dc.description.sponsorshipThe authors gratefully acknowledge “Enamine Ltd.” (Kyiv, Ukraine) for fnancial support of this work, and team of the Drug Synthesis and Chemistry Branch, National Cancer Institute, Bethesda, MD, USA, for in vitro evaluation of anticancer activity.uk_UK
dc.identifier.citationSynthesis, anticancer and FGFR1 inhibitory activity of isoindolo isoindolo[2,1-a][1,2,4]triazino[2,3-c]quinazoline derivatives / O. Yu. Voskoboynik [et al.] // Медична та клінічна хімія. - 2016. - Т. 18, № 1. – P. 5-18.uk_UK
dc.identifier.issn2410-681X
dc.identifier.urihttps://zsmu.rosbai.com/handle/123456789/4784
dc.language.isoenuk_UK
dc.publisherТДМУuk_UK
dc.subjectisoindolesuk_UK
dc.subjecttriazinesuk_UK
dc.subjectquinazolinesuk_UK
dc.subjectanticancer activityuk_UK
dc.subjectFGFR1 inhibitory activityuk_UK
dc.subjectdockinguk_UK
dc.titleSynthesis, anticancer and FGFR1 inhibitory activity of isoindolo isoindolo[2,1-a][1,2,4]triazino[2,3-c]quinazoline derivativesuk_UK
dc.title.alternativeСинтез, протиракова та FGFR1 інгібуюча активність похідних ізоіндоло[2,1-a][1,2,4]триазино[2,3-c]хіназолінуuk_UK
dc.typeArticleuk_UK

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
6123-21693-1-SM (1).pdf
Size:
905.14 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
2.13 KB
Format:
Plain Text
Description: